New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
Clarity Pharmaceuticals announced preliminary SECuRE trial results showing 74% of participants achieved PSA25 and 81% disease control with 8 GBq 67Cu-SAR-bisPSMA. A 76-year-old patient achieved undetectable disease after two cycles, and shares rose 14%.
FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive cholangiocarcinoma on May 8, 2026. The eNRGy trial showed a 36.8% ORR. It also received priority review, breakthrough, and orphan designations.
The FDA approved pivekimab sunirine-pvzy (Decnupaz) for adults with BPDCN on May 27, 2026, based on CADENZA trial data showing a 69.7% CR/CRc rate in treatment-naïve patients.
Vaccine denial and weakened public health measures risk increasing chronic illness, as historical data shows post-infectious conditions follow major outbreaks. Long COVID affects 10-20% of those infected, while historical pandemics led to conditions like encephalitis lethargica with near 50% mortality.
The treatment landscape for multiple myeloma is evolving rapidly with T-cell engaging therapies like bispecific antibodies and CAR T-cell treatments shifting care toward a chronic condition with potential treatment breaks. This evolution is creating new side effect management challenges and complicating clinical trial design as sponsors grapple with selecting comparator arms and adapting to a rapidly shifting standard of care.
Two new studies reveal long COVID's lasting biological and mental health effects. A mouse study found coronavirus triggers prolonged lung and brain damage unlike influenza, while a population study linked long COVID to significantly higher depression and anxiety risks up to three years post-infection.
Acromegaly patients face persistent symptoms including fatigue, joint pain, headaches, and brain fog despite biochemical control. Treatment burden and financial barriers remain significant, particularly in sub-Saharan Africa where diagnostic tools and therapies are often inaccessible.
Telix said Part 1 of the ProstACT Global Phase 3 study met its primary objectives for TLX591-Tx in mCRPC. The company reported acceptable safety, no new safety signals and progression plans for Part 2.
Nereus (tradipitant) is now commercially available for prevention of motion-induced vomiting. Vanda has launched a phase 3 trial in GLP-1 users, building on phase 2 results showing a 50% relative reduction in vomiting.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779382 |
A Clinical Trial to Evaluate the Effects of a Topical Roll-on and Diffuser Blend on Sleep Quality and Sleep Duration |
COMPLETED | NA |
| NCT07755475 |
A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels |
COMPLETED | NA |
| NCT07752459 |
Physiological Responses to Basketball-Specific Interval Exercise in Female Basketball Players |
NOT_YET_RECRUITING | NA |
| NCT07752329 |
Investigation on the Chronic Effects of Nepalese Pepper (Zanthoxylum Armatum DC) on Cognitive Function, Mood and Gaming Performance in Young, Healthy, Action Video Gamers |
NOT_YET_RECRUITING | NA |
| NCT07747285 |
POSH-Ex: Physiotherapist-Led Telerehabilitation Exercise Programme for Postpartum Sexual Health |
NOT_YET_RECRUITING | NA |
| NCT07747064 |
Effects of Taekwondo Match-Simulated Fatigue on Balance Performance in Female Athletes |
NOT_YET_RECRUITING | NA |
| NCT07746011 |
A Clinical Trial to Evaluate the Effects of EMF Protection Devices on Sleep and Energy Levels |
COMPLETED | NA |
| NCT07745010 |
Radicle Energy™ DNB: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes |
NOT_YET_RECRUITING | NA |
| NCT07738744 |
A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Liver and Digestive Health |
COMPLETED | NA |
| NCT07735273 |
eMindExCare for Prostate Cancer Patients Undergoing Active Treatment |
NOT_YET_RECRUITING | NA |
